PSMC3 proteasome subunit variants are associated with neurodevelopmental delay and type I interferon production

Frédéric Ebstein1, Sébastien Küry2,3, Victoria Most4

  • 1Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

PubMed

Insights

New variants in the PSMC3 gene cause neurodevelopmental disorders by disrupting proteasome function. This proteotoxic stress impacts brain development and immune responses, offering new insights into disease pathogenesis.

Area of Science:

  • Genetics
  • Neuroscience
  • Immunology

Background:

  • Protein homeostasis is vital, involving proteasome subunits like PSMC1-6 for protein degradation.
  • The 26S proteasome plays a crucial role in cellular protein turnover.

Purpose of the Study:

  • To investigate the role of PSMC3 gene variants in neurodevelopmental disorders.
  • To understand the molecular mechanisms underlying proteasome dysfunction caused by PSMC3 variants.

Main Methods:

  • Identification of de novo missense variants in the PSMC3 gene in patients.
  • Expression of PSMC3 variants in mouse neuronal cultures and Drosophila models.
  • Proteomic and transcriptomic analyses of patient-derived T cells.
  • Structural modeling of PSMC3 variants.

Main Results:

  • 15 de novo PSMC3 variants were found in patients with neurodevelopmental delay and intellectual disability.
  • PSMC3 variants impaired neuronal development in mice and learning in flies.
  • Variants disrupted proteasome function, induced proteotoxic stress, and altered developmental and immune proteins.
  • Proteostatic perturbations correlated with dysregulated type I interferon signaling via protein kinase R (PKR).

Conclusions:

  • PSMC3 variants cause proteasome dysfunction, leading to proteotoxic stress and neurodevelopmental issues.
  • The study reveals a link between proteasome dysfunction, PKR activation, type I interferon response, and neurodevelopmental disorders.
  • These findings suggest novel therapeutic avenues targeting proteasome function and immune signaling in neurodevelopmental conditions.